Transgender youth on puberty blockers and gender-affirming hormones have lower rates of depression and suicidal thoughts, a new study finds
- Written by Diana Tordoff, PhD Candidate in Epidemiology, University of Washington
Recent studies estimate that 1.8%[1] to 2.7%[2] – or approximately 750,000 to 1.1 million – adolescents in the U.S. identify as transgender or nonbinary. Many of these trans youth experience high levels of negative mental health symptoms due to anti-transgender stigma, discrimination and lack of family or peer support. A 2021 study[3] found that as much as 72% of trans youth were depressed, and half had seriously considered suicide.
We are an epidemiologist[4] and fourth-year medical student who study ways to make clinical care more inclusive for trans and nonbinary people. We conducted a study[5] in collaboration with the Seattle Children’s Hospital Gender Clinic[6] that found that transgender youth on puberty blockers and gender-affirming hormone therapy are less likely to report depression and suicidal thoughts.
Safe and proven treatments
Puberty blockers[7] are medications that delay puberty. By temporarily stopping the body from making the hormones that lead to puberty-related changes, young people and their families are given time to pause and make health decisions. These medications have been used for over 30 years[8] to treat young people with puberty that starts too early, also called precocious puberty[9].
Gender-affirming hormone therapy, like testosterone[10] or estrogen[11], are medications that allow trans youth to experience a puberty appropriately aligned with their gender.
There is no shortage of scientific and clinical societies that have found these medications to be both safe and effective for transgender people. Numerous medical and professional societies[12], including the American Academy of Pediatrics[13], the American Academy of Child and Adolescent Psychiatry[14] and the American Medical Association[15], endorse access to gender-affirming care specifically for trans youth.
Social support[16], as well as access to gender-affirming care[17], is known to significantly reduce poor mental health in trans youth. In addition, several recent studies have suggested that early access to puberty blockers[18] and hormones[19] during adolescence can have long-term positive effects that last into adulthood. Despite these benefits, many young people face significant barriers in accessing gender-affirming care. Only 1 in 5 youth[20] who need hormones have been able to access them.
To further examine the mental health effects of puberty blockers and hormone therapy, we followed 104 trans and nonbinary youth ages 13 to 20 during their first year of gender-affirming care. After one year, we found that young people who began puberty blockers or gender-affirming hormones were 60% less likely to be depressed and 73% less likely to have thoughts about self-harm or suicide compared to youth who hadn’t started these medications.
In addition, young people who were unable to start these medications within three to six months of their first appointment with a medical provider had a two- to threefold increase in depression and suicidal thoughts. Our findings suggest that delays in prescribing hormones and puberty blockers may worsen mental health symptoms for trans youth.
What this means for anti-transgender legislation
2021 and 2022 have been record-breaking years for anti-transgender legislation[22], including attempts to criminalize gender-affirming care[23] for trans youth.
[Over 140,000 readers rely on The Conversation’s newsletters to understand the world. Sign up today[24].]
Banning gender-affirming care will have immediate and long-term negative effects on the well-being of trans youth and their families, both by increasing the stigma and discrimination these young people face and by denying them access to critical life-saving and evidence-based health care. Our study builds on existing scientific evidence and underscores that timely access to gender-affirming care saves trans youth lives.
References
- ^ 1.8% (dx.doi.org)
- ^ 2.7% (doi.org)
- ^ 2021 study (doi.org)
- ^ epidemiologist (www.dianatordoff.com)
- ^ study (jamanetwork.com)
- ^ Seattle Children’s Hospital Gender Clinic (www.seattlechildrens.org)
- ^ Puberty blockers (health.clevelandclinic.org)
- ^ over 30 years (dx.doi.org)
- ^ precocious puberty (www.mayoclinic.org)
- ^ testosterone (transcare.ucsf.edu)
- ^ estrogen (transcare.ucsf.edu)
- ^ Numerous medical and professional societies (www.aap.org)
- ^ American Academy of Pediatrics (doi.org)
- ^ American Academy of Child and Adolescent Psychiatry (www.aacap.org)
- ^ American Medical Association (www.ama-assn.org)
- ^ Social support (doi.org)
- ^ gender-affirming care (www.psychologytoday.com)
- ^ puberty blockers (doi.org)
- ^ hormones (doi.org)
- ^ 1 in 5 youth (doi.org)
- ^ AP Photo/Eric Gay (newsroom.ap.org)
- ^ anti-transgender legislation (doi.org)
- ^ criminalize gender-affirming care (twitter.com)
- ^ Sign up today (memberservices.theconversation.com)
Authors: Diana Tordoff, PhD Candidate in Epidemiology, University of Washington
